CDT

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

Retrieved on: 
torsdag, maj 30, 2024
Doctor of Philosophy, Rachel Haurwitz, University, CDT, Conference, Bone marrow, CLL, Lymphoma, MD, Medicine, CRISPR, University of Utah, Hematology, Medical College of Wisconsin, Management

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences:

Key Points: 
  • BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences:
    June 2, 2024, CB-010 ANTLER Phase 1 clinical trial data in r/r B-NHL to be shared in a press release at 6:00 pm CDT followed by a live webcast of a discussion with KOLs and management at 7:00 pm CDT.
  • The presenters will include:
    Boyu Hu, MD, director of lymphoma and CLL in the division of hematology and hematologic malignancies, University of Utah
    Mehdi Hamadani, MD, professor of medicine, section chief of hematologic malignancies, Medical College of Wisconsin
    Rachel Haurwitz, PhD, president and chief executive officer, Caribou Biosciences
    Additional participants from Caribou Biosciences include:
    • Jefferies Global Healthcare Conference, New York, NY
    • Goldman Sachs 45th Annual Global Healthcare Conference, Miami, FL

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO® Annual Meeting

Retrieved on: 
torsdag, maj 30, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Relapse, Follicular lymphoma, Paclitaxel, Finish line, Drug development, Metastatic breast cancer, Breast cancer, Tumor microenvironment, Sarah Cannon Research Institute, Breast, Lead, Master, Consolidation, HealthOne, Durvalumab, Meta-analysis, CDT, OU Health, Total cost, PD-L1, Survival, Clinical trial, Quality, MPH, Endometrial cancer, NSCLC, SCRI, ASCO, Safety, BCMA, Society, Cetuximab, Doctor of Philosophy, Efficacy, Spacecraft, Metastasis, Monoclonal antibody, Acute myeloid leukemia, Abstract, HCA Healthcare, Role, Annual general meeting, Birth control

“We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.

Key Points: 
  • “We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.
  • To learn more about our research experts, visit our Leadership Page .
  • “Clinical Trial Participation and End-of-Life Care Among Older Adults: A Multi-Center Longitudinal Observational Cohort Analysis of 121,717 Patients with Cancer,” Dr.
  • “Performance of Comprehensive Genomic Profiling versus Single Gene Testing in Guideline-Recommended Biomarker Selection in Non-Small Cell Lung Cancer,” Dr. V. Subbiah, 1:30 p.m. - 4:30 p.m. CDT, Hall A.

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

Retrieved on: 
onsdag, maj 29, 2024
Presidio, CDT, Conduit, SAN, Trust, Growth, Cryptocurrency

A preliminary list of index additions, including Conduit, was posted by FTSE Russell on May 24, 2024.

Key Points: 
  • A preliminary list of index additions, including Conduit, was posted by FTSE Russell on May 24, 2024.
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
  • “We are excited the additional visibility that being in the Russell 2000 and Russell 3000 will give Conduit,” said Jack Heilbron, President and Chief Executive Officer of Presidio.
  • Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

Watsco to Present at William Blair’s 44th Annual Growth Stock Conference in Chicago on June 4, 2024 at 3:20 p.m. CDT

Retrieved on: 
onsdag, maj 29, 2024
Conference, WSO, CDT, Watsco, Loews Hotel Tower

MIAMI, May 29, 2024 (GLOBE NEWSWIRE) -- Watsco, Inc. (NYSE: WSO) announced today that Barry Logan, Executive Vice President, is scheduled to present at the William Blair 44th Annual Growth Stock Conference being held at the Loews Chicago Hotel on Tuesday, June 4, 2024 at 3:20 p.m. (CDT).

Key Points: 
  • MIAMI, May 29, 2024 (GLOBE NEWSWIRE) -- Watsco, Inc. (NYSE: WSO) announced today that Barry Logan, Executive Vice President, is scheduled to present at the William Blair 44th Annual Growth Stock Conference being held at the Loews Chicago Hotel on Tuesday, June 4, 2024 at 3:20 p.m. (CDT).
  • Internet users can listen to a live webcast of the presentation at the Investor Relations section of Watsco’s website at http://www.watsco.com .

Rockwell Automation to Present at Wells Fargo Industrials Conference

Retrieved on: 
tisdag, maj 28, 2024
Electronic Design Automation, Technology, Manufacturing, Other Technology, Software, Other Manufacturing, Machinery, Senior, Conference, Automation, CDT, Rockwell Automation

Rockwell Automation, Inc. (NYSE: ROK) Senior Vice President, Intelligent Devices, Tessa Myers, and Vice President, Investor Relations and Market Strategy, Aijana Zellner, will present at Wells Fargo Industrials Conference on Tuesday, June 11, 2024, in Chicago, Illinois.

Key Points: 
  • Rockwell Automation, Inc. (NYSE: ROK) Senior Vice President, Intelligent Devices, Tessa Myers, and Vice President, Investor Relations and Market Strategy, Aijana Zellner, will present at Wells Fargo Industrials Conference on Tuesday, June 11, 2024, in Chicago, Illinois.
  • The fireside chat will be webcast beginning at approximately 11:00 a.m. CDT and will be available on the Rockwell Automation Investor Relations website at www.rockwellautomation.com/en-us/investors.html .

Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®

Retrieved on: 
tisdag, maj 28, 2024
Research, General Health, Pharmaceutical, Optical, Specialty, Retail, Clinical Trials, Science, Surgery, Medical Supplies, FDA, Health, The Bell Tower, Trial of the century, Viral, Bausch, Allergy, OD, Inflammation, Steroid, Fungal infection, Action, OnDemand, AOA, Telecanthus, CDT, Glaucoma, Sclera, Infection, Intraocular pressure, Contact, American Optometric Association, Conjunctiva, Cerebral edema, Music City Center, Macular edema, Complex, Eye injury, Thought, System, Employment, Convention, Contact lens, Slit lamp, Vaccinia, Patient, Incidence, Safety, Keratitis, Bausch & Lomb, Herpes simplex, Visual acuity, Taste, Iris, Eyelash, Risk, IOP, Lens (vertebrate anatomy), Astigmatism, Pigment, Efficacy, Verge, Ocular hypertension, Eye, Abstract, Human, Pain, Optic nerve, History, Palm, Chickenpox, EYE

The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.

Key Points: 
  • The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.
  • “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et al.
  • “Improvement in Non-Invasive Tear Break-Up Time after Instillation of One Drop of Brimonidine Tartrate 0.025%.” Moore et al.
  • During the event, attendees will have the opportunity to learn about Bausch + Lomb’s latest innovations, including Bausch + Lomb INFUSE® for Astigmatism and Blink NutriTears.

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Plantar fibromatosis, Patient, Decentralized finance, Date, NDA, CDT, FDA, EDT, Therapy, Safety, MEK, Neoplasm, Cancer, ASCO, Abstract, Society, Sympathetic nervous system, Pain, Pharmaceutical industry

STAMFORD, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that four abstracts from the company's portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 to June 4, 2024.

Key Points: 
  • STAMFORD, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that four abstracts from the company's portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 to June 4, 2024.
  • In addition, three new data sets from the pivotal Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors will be presented at ASCO.
  • The DeFi trial developed one of the most comprehensive assessments of ovarian function in an oncology clinical trial to date.
  • Of the 142 patients in the DeFi trial intent-to-treat population, 29 had identified APC mutations (nirogacestat, N=13; placebo, N=16).

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
IOV, Interleukin, McCormick Place, ICI, Patient, TIL, Pembrolizumab, Cohort, Food, Clinical trial, CDT, FDA, EDT, Disease, Safety, SAN, RECIST, Cancer, Melanoma, ASCO, Webcast, Pharmaceutical industry

SAN CARLOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting to be held May 31 – June 4, 2024, at McCormick Place in Chicago, IL and online.

Key Points: 
  • Unprecedented response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïve to immune checkpoint inhibitor (ICI) therapy.
  • Confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses by RECIST v1.1.
  • TILVANCE-301 is a global, randomized, registrational Phase 3 trial to support accelerated and full U.S. approvals of lifileucel in combination with pembrolizumab in frontline advanced melanoma.
  • The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com for one year.

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

Retrieved on: 
torsdag, maj 23, 2024
ABL, Patient, Doctor of Philosophy, HealthOne, Immunotherapy, Ovarian cancer, CDT, PFS, Safety, KOSDAQ, PRS, Neoplasm, Efficacy, Abstract, Cancer, Interim, ASCO, Monoclonal antibody, Society, CBR, Observation, Hepatotoxicity, Pharmaceutical industry

Ragistomig was designed as a bispecific antibody to provide anti-PD-L1 activity and 4-1BB-driven T-cell activation in one molecule.

Key Points: 
  • Ragistomig was designed as a bispecific antibody to provide anti-PD-L1 activity and 4-1BB-driven T-cell activation in one molecule.
  • “We are pleased to present the Phase 1 data to date for ragistomig at ASCO 2024.
  • These data support further development of ragistomig as both a monotherapy and in combination with other compounds.
  • Observation of responses is also encouraging, including a 25% ORR and a 75% clinical benefit rate (CBR), at the optimal dose of 5 mg/kg.

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

Retrieved on: 
torsdag, maj 23, 2024
Patient, MTD, Food, Neutropenia, University, CDT, FDA, ABW, SAN, Castration, ADC, Peripheral neuropathy, Prostate cancer, MMAE, Spacecraft, CD46, ASCO, Enza, Fatigue, Society, Weight loss, Arsis, Principal, Annual general meeting, Pharmaceutical industry

“We are excited to announce that FG-3246 in combination with enzalutamide in patients with mCRPC demonstrated clinically meaningful early signals of efficacy,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.

Key Points: 
  • “We are excited to announce that FG-3246 in combination with enzalutamide in patients with mCRPC demonstrated clinically meaningful early signals of efficacy,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Over 70% of the patients in the study received at least two prior ARSIs, which included prior enzalutamide treatment.
  • The primary endpoint was determination of the maximally tolerated dose (MTD) of FG-3246 in combination with enzalutamide.
  • The MTD was established at 2.1 mg/kg ABW, with primary G-CSF prophylaxis, in combination with enzalutamide 160 mg/day.